Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
ETON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.18 - $21.48
Previous CloseN/A
Volume127.06K
Average Volume (3M)405.02K
Market Cap
$380.00M
Enterprise Value$61.13M
Total Cash (Recent Filing)$17.42M
Total Debt (Recent Filing)$87.00K
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 07, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding26,817,535
10 Day Avg. Volume506,563
30 Day Avg. Volume405,020
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)5.42
Price to Sales (P/S)0.00
P/FCF Ratio34.88
Enterprise Value/Market Cap0.16
Enterprise Value/Revenue0.40
Enterprise Value/Gross Profit2.16
Enterprise Value/Ebitda-5.01
Forecast
1Y Price Target
$29.67Price Target Upside109.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Eton Pharmaceuticals News
PremiumCompany Announcements
Eton Pharmaceuticals Holds Annual Stockholders Meeting
PremiumCompany Announcements
Eton Pharmaceuticals Gains FDA Approval for KHINDIVI
PremiumCompany Announcements
Eton Pharmaceuticals’ Earnings Call: Growth and Prospects
Bulls Say, Bears Say
Bulls Say
FDA ApprovalKhindivi received FDA approval as replacement therapy in pediatric patients 5 years of age and older with adrenal insufficiency.
Product LaunchThe management plans to launch Khindivi immediately and has shown strong commercial execution.
Revenue GrowthEton Pharmaceuticals has reported 16 sequential quarters of growth, with a 4Q top-line beat and 12% sequential growth.
Bears Say
Financial GuidanceManagement provided conservative financial guidance of $80M in annual revenue run-rate by year-end 2025, suggesting potential for exceeding current expectations.
Market Expansion ChallengesThere is potential for Increlex's SPIGFD population expansion through U.S./EU label unification, increasing the number of treatable patients.
Product DevelopmentThe company is developing ET-700 to offer an extended-release formulation of zinc, targeting a significant patient population with potential for high revenue.
Options Prices
Currently, No data available
---
Ownership Overview
15.17% Insiders
6.59% Mutual Funds
33.69% Other Institutional Investors
40.34% Public Companies and Individual Investors
ETON FAQ
What was Eton Pharmaceuticals Inc’s price range in the past 12 months?
Eton Pharmaceuticals Inc lowest stock price was $3.18 and its highest was $21.48 in the past 12 months.
What is Eton Pharmaceuticals Inc’s market cap?
Eton Pharmaceuticals Inc’s market cap is $380.00M.
When is Eton Pharmaceuticals Inc’s upcoming earnings report date?
Eton Pharmaceuticals Inc’s upcoming earnings report date is Aug 07, 2025 which is in 50 days.
How were Eton Pharmaceuticals Inc’s earnings last quarter?
Eton Pharmaceuticals Inc released its earnings results on May 13, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of $0.053 by -$0.113.
Is Eton Pharmaceuticals Inc overvalued?
According to Wall Street analysts Eton Pharmaceuticals Inc’s price is currently Undervalued.
Does Eton Pharmaceuticals Inc pay dividends?
Eton Pharmaceuticals Inc does not currently pay dividends.
What is Eton Pharmaceuticals Inc’s EPS estimate?
Eton Pharmaceuticals Inc’s EPS estimate is <0.01.
How many shares outstanding does Eton Pharmaceuticals Inc have?
Eton Pharmaceuticals Inc has 26,817,535 shares outstanding.
What happened to Eton Pharmaceuticals Inc’s price movement after its last earnings report?
Eton Pharmaceuticals Inc reported an EPS of -$0.06 in its last earnings report, missing expectations of $0.053. Following the earnings report the stock price went up 0.293%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ETON
Eton Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.67 (109.39% Upside)
$29.67 (109.39% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
298.03%
12-Months-Change
Fundamentals
Return on Equity
-22.95%
Trailing 12-Months
Asset Growth
172.88%
Trailing 12-Months
Company Description
Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Eton Pharmaceuticals demonstrated strong revenue growth and successful product launches, particularly with Increlex and Galzin. However, the company faces challenges with increased operating expenses and a net loss for the quarter. Despite these lowlights, the overall performance and future prospects indicate a positive trend.Read More>ETON Stock 12 Month Forecast
Average Price Target
$29.67
▲(109.39%Upside)
Technical Analysis
Heron Therapeutics
―
Benitec Biopharma
―
Mereo Biopharma Group Plc
―
Tectonic Therapeutic
―
AbSci
―